Journal of Health and Medical Sciences
ISSN 2622-7258
Published: 22 September 2022
Guillain-Barré Syndrome: A Case Report of Post Covid-19 Vaccination in the Philippines
Paul Nichol G. Gonzales, Steven G. Villaraza, Aubrey M. Punzalan-Sotelo
Jose R. Reyes Memorial Medical Center
Download Full-Text Pdf
10.31014/aior.1994.05.03.237
Pages: 276-282
Keywords: Guillain-Barre, Covid-19, Vaccination
Abstract
Guillain-Barré Syndrome (GBS) is a complex autoimmune disorder where a person’s own immune system damages the nerve and is usually characterized by ascending symmetrical weakness of the upper and lower extremities (Wijdicks & Klein, 2017). It is a rare condition and the worldwide frequency of GBS is only 2 in 100,000 adult individuals (McGrogan et al., 2009). Studies have shown its association with different vaccines but in these pandemic times, there is a lack of literature on post-COVID-19 vaccination-associated GBS. We report a case of a 68-year-old male from Caloocan City with an initial complaint of febrile illness followed by distal lower extremity weakness which started seven (7) days after the patient received his first Sinovac-CoronaVac vaccine. We report a case of GBS that is related to the Sinovac-CoronaVac vaccine which adds to the body of literature that is currently available and may reflect a possible link.
References
Forsberg, A., Press, R., Einarsson, U., de Pedro-Cuesta, J., & Widén Holmqvist, L. (2004). Impairment in Guillain–Barré syndrome during the first 2 years after onset: A prospective study. Journal of the Neurological Sciences, 227(1), 131–138. https://doi.org/10.1016/j.jns.2004.09.021
Haber, P., Sejvar, J., Mikaeloff, Y., & DeStefano, F. (2009). Vaccines and Guillain-Barré Syndrome: Drug Safety, 32(4), 309–323. https://doi.org/10.2165/00002018-200932040-00005
Hughes, R. A. C. (1990). Pathology of Guillain-Barré Syndrome. In M. Swash (Ed.), Guillain-Barré Syndrome (pp. 83–100). Springer London. https://doi.org/10.1007/978-1-4471-3175-5_4
Hughes, R. A., & Cornblath, D. R. (2005). Guillain-Barré syndrome. The Lancet, 366(9497), 1653–1666. https://doi.org/10.1016/S0140-6736(05)67665-9
Hughes, R. A., Swan, A. V., van Koningsveld, R., & van Doorn, P. A. (2006). Corticosteroids for Guillain-Barré syndrome. In The Cochrane Collaboration (Ed.), Cochrane Database of Systematic Reviews (p. CD001446.pub2). John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD001446.pub2
Khan, Z., Ahmad, U., Ualiyeva, D., Amissah, O. B., Khan, A., Noor, Z., & Zaman, N. (2022). Guillain-Barre syndrome: An autoimmune disorder post-COVID-19 vaccination? Clinical Immunology Communications, 2, 1–5. https://doi.org/10.1016/j.clicom.2021.12.002
Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., Kusunoki, S., Pardo, C. A., Reisin, R., Sejvar, J. J., Shahrizaila, N., Soares, C., Umapathi, T., Wang, Y., Yiu, E. M., … Jacobs, B. C. (2019). Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology, 15(11), 671–683. https://doi.org/10.1038/s41582-019-0250-9
McGrogan, A., Madle, G. C., Seaman, H. E., & de Vries, C. S. (2009). The Epidemiology of Guillain-Barré Syndrome Worldwide. Neuroepidemiology, 32(2), 150–163. https://doi.org/10.1159/000184748
Miravalle, A., Biller, J., Schnitzler, E., & Bonwit, A. (2010). Neurological complications following vaccinations. Neurological Research, 32(3), 285–292. https://doi.org/10.1179/016164110X12645013515214
Omer, S. B., Yildirim, I., & Forman, H. P. (2020). Herd Immunity and Implications for SARS-CoV-2 Control. JAMA, 324(20), 2095. https://doi.org/10.1001/jama.2020.20892
Salmon, D. A., Proschan, M., Forshee, R., Gargiullo, P., Bleser, W., Burwen, D. R., Cunningham, F., Garman, P., Greene, S. K., Lee, G. M., Vellozzi, C., Yih, W. K., Gellin, B., & Lurie, N. (2013). Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: A meta-analysis. The Lancet, 381(9876), 1461–1468. https://doi.org/10.1016/S0140-6736(12)62189-8
Sejvar, J. J., Kohl, K. S., Gidudu, J., Amato, A., Bakshi, N., Baxter, R., Burwen, D. R., Cornblath, D. R., Cleerbout, J., Edwards, K. M., Heininger, U., Hughes, R., Khuri-Bulos, N., Korinthenberg, R., Law, B. J., Munro, U., Maltezou, H. C., Nell, P., Oleske, J., … Wiznitzer, M. (2011). Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 29(3), 599–612. https://doi.org/10.1016/j.vaccine.2010.06.003
Shao, S.-C., Wang, C.-H., Chang, K.-C., Hung, M.-J., Chen, H.-Y., & Liao, S.-C. (2021). Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerging Infectious Diseases, 27(12), 3175–3178. https://doi.org/10.3201/eid2712.211634
Visser, L., van der Meche, F., Meulstee, J., van Doorn, P., & the Dutch Guillain-Barre study group. (1998). Risk factors for treatment related clinical fluctuations in Guillain-Barre syndrome. Journal of Neurology, Neurosurgery & Psychiatry, 64(2), 242–244. https://doi.org/10.1136/jnnp.64.2.242
Waheed, S., Bayas, A., Hindi, F., Rizvi, Z., & Espinosa, P. S. (2021). Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus. https://doi.org/10.7759/cureus.13426
Walgaard, C., Lingsma, H. F., Ruts, L., van Doorn, P. A., Steyerberg, E. W., & Jacobs, B. C. (2011). Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology, 76(11), 968–975. https://doi.org/10.1212/WNL.0b013e3182104407
Wijdicks, E. F. M., & Klein, C. J. (2017). Guillain-Barré Syndrome. Mayo Clinic Proceedings, 92(3), 467–479. https://doi.org/10.1016/j.mayocp.2016.12.002